Leap Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Cypherpunk Technologies

21/03/2025 13:01

Leap Therapeutics Inc LPTX.OQ LPTX.O is expected to show no change in quarterly revenue when it reports  results on March 24 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Leap Therapeutics Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Leap Therapeutics Inc is $3.00​, above​ its last closing price of $0.41. ​​​

This summary was machine generated March 21 at 13:00 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)